inclusion criteria: a study participant will be eligible for inclusion in this study only if all the following criteria apply: 1 male and female participants 18 - 70 years of age. 2. participants in the study have proof of post covid-19 syndrome in their medical records. 3. study participants must have been diagnosed with chronic post-covid-19 syndrome for at least twelve weeks before enrollment in the clinical trial. 4. the study participant is experiencing one or more neurological symptoms for at least 12 weeks, either continually or intermittently, with relapses not experienced pre-illness that interferes with regular daily activities. symptoms must be new symptoms or dramatic worsening of preexisting symptoms, i.e., the subject didn't have symptoms and had not sought medical treatment for the symptoms before covid-19, or the symptoms are dramatically worse (in severity and frequency). at least one symptom must have a severity of "5cm" on the neurological symptom vas at screening. see the list of symptoms below: * extreme fatigue: feeling overtired with low energy and a strong desire to sleep. * brain fog: a diminished mental capacity marked by the inability to concentrate, think or reason clearly interferes with daily activities. * headache: sharp or dull reoccurring or intermittent that were not present pre-illness. * sleep issues: any sleep disturbances in sleep quality that makes sleep seem inadequate or unrefreshing like insomnia or hypersomnia. * loss of taste/smell: a diminished sense of taste or smell. 5. study participants should be able to read, understand, and provide written consent. 6. female study participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration. 7. if their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after the last administration of the experimental drug. \* 8. the study participant is able and willing to comply with the requirements of this clinical trial.

inclusion criteria: a study participant will be eligible for inclusion in this study only if all the following criteria apply: 1 male and female participants 18 - 70 years of age. 2. participants in the study have proof of post covid-19 syndrome in their medical records. 3. study participants must have been diagnosed with chronic post-covid-19 syndrome for at least twelve weeks before enrollment in the clinical trial. 4. the study participant is experiencing one or more neurological symptoms for at least 12 weeks, either continually or intermittently, with relapses not experienced pre-illness that interferes with regular daily activities. symptoms must be new symptoms or dramatic worsening of preexisting symptoms, i.e., the subject didn't have symptoms and had not sought medical treatment for the symptoms before covid-19, or the symptoms are dramatically worse (in severity and frequency). at least one symptom must have a severity of "5cm" on the neurological symptom vas at screening. see the list of symptoms below: * extreme fatigue: feeling overtired with low energy and a strong desire to sleep. * brain fog: a diminished mental capacity marked by the inability to concentrate, think or reason clearly interferes with daily activities. * headache: sharp or dull reoccurring or intermittent that were not present pre-illness. * sleep issues: any sleep disturbances in sleep quality that makes sleep seem inadequate or unrefreshing like insomnia or hypersomnia. * loss of taste/smell: a diminished sense of taste or smell. 5. study participants should be able to read, understand, and provide written consent. 6. female study participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration. 7. if their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after the last administration of the experimental drug. \* 8. the study participant is able and willing to comply with the requirements of this clinical trial.

inclusion criteria: a study participant will be eligible for inclusion in this study only if all the following criteria apply: 1 male and female participants 18 - 70 years of age. 2. participants in the study have proof of post covid-19 syndrome in their medical records. 3. study participants must have been diagnosed with chronic post-covid-19 syndrome for at least twelve weeks before enrollment in the clinical trial. 4. the study participant is experiencing one or more neurological symptoms for at least 12 weeks, either continually or intermittently, with relapses not experienced pre-illness that interferes with regular daily activities. symptoms must be new symptoms or dramatic worsening of preexisting symptoms, i.e., the subject didn't have symptoms and had not sought medical treatment for the symptoms before covid-19, or the symptoms are dramatically worse (in severity and frequency). at least one symptom must have a severity of "5cm" on the neurological symptom vas at screening. see the list of symptoms below: extreme fatigue: feeling overtired with low energy and a strong desire to sleep. brain fog: a diminished mental capacity marked by the inability to concentrate, think or reason clearly interferes with daily activities. headache: sharp or dull reoccurring or intermittent that were not present pre-illness. sleep issues: any sleep disturbances in sleep quality that makes sleep seem inadequate or unrefreshing like insomnia or hypersomnia. loss of taste/smell: a diminished sense of taste or smell. 5. study participants should be able to read, understand, and provide written consent. 6. female study participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration. 7. if their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after the last administration of the experimental drug. * 8. the study participant is able and willing to comply with the requirements of this clinical trial.

inclusion criteria: a study participant will be eligible for inclusion in this study only if all the following criteria apply: 1 male and female participants 18 - 70 years of age. 2. participants in the study have proof of post covid-19 syndrome in their medical records. 3. study participants must have been diagnosed with chronic post-covid-19 syndrome for at least twelve weeks before enrollment in the clinical trial. 4. the study participant is experiencing one or more neurological symptoms for at least 12 weeks, either continually or intermittently, with relapses not experienced pre-illness that interferes with regular daily activities. symptoms must be new symptoms or dramatic worsening of preexisting symptoms, i.e., the subject didn't have symptoms and had not sought medical treatment for the symptoms before covid-19, or the symptoms are dramatically worse (in severity and frequency). at least one symptom must have a severity of "5cm" on the neurological symptom vas at screening. see the list of symptoms below: extreme fatigue: feeling overtired with low energy and a strong desire to sleep. brain fog: a diminished mental capacity marked by the inability to concentrate, think or reason clearly interferes with daily activities. headache: sharp or dull reoccurring or intermittent that were not present pre-illness. sleep issues: any sleep disturbances in sleep quality that makes sleep seem inadequate or unrefreshing like insomnia or hypersomnia. loss of taste/smell: a diminished sense of taste or smell. 5. study participants should be able to read, understand, and provide written consent. 6. female study participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration. 7. if their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after the last administration of the experimental drug. * 8. the study participant is able and willing to comply with the requirements of this clinical trial.

inclusion criteria: 1 male and female participants 18 - 70 years of age. 2. participants in the study have proof of post covid-19 syndrome in their medical records. 3. study participants must have been diagnosed with chronic post-covid-19 syndrome for at least twelve weeks before enrollment in the clinical trial. 4. the study participant is experiencing one or more neurological symptoms for at least 12 weeks, either continually or intermittently, with relapses not experienced pre-illness that interferes with regular daily activities. symptoms must be new symptoms or dramatic worsening of preexisting symptoms, i.e., the subject didn't have symptoms and had not sought medical treatment for the symptoms before covid-19, or the symptoms are dramatically worse (in severity and frequency). at least one symptom must have a severity of "5cm" on the neurological symptom vas at screening. see the list of symptoms below: extreme fatigue: feeling overtired with low energy and a strong desire to sleep brain fog: a diminished mental capacity marked by the inability to concentrate, think or reason clearly interferes with daily activities. headache: sharp or dull reoccurring or intermittent that were not present pre-illness. sleep issues: any sleep disturbances in sleep quality that makes sleep seem inadequate or unrefreshing like insomnia or hypersomnia. loss of taste/smell: a diminished sense of taste or smell. 5. study participants should be able to read, understand, and provide written consent. 6. female study participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration. 7. if their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after the last administration of the experimental drug. * 8. the study participant is able and willing to comply with the requirements of this clinical trial.

inclusion criteria: 1 male and female participants 18 - 70 years of age. 2. participants in the study have proof of post covid-19 syndrome in their medical records. 3. study participants must have been diagnosed with chronic post-covid-19 syndrome for at least twelve weeks before enrollment in the clinical trial. 4. the study participant is experiencing one or more neurological symptoms for at least 12 weeks, either continually or intermittently, with relapses not experienced pre-illness that interferes with regular daily activities. symptoms must be new symptoms or dramatic worsening of preexisting symptoms, i.e., the subject didn't have symptoms and had not sought medical treatment for the symptoms before covid-19, or the symptoms are dramatically worse (in severity and frequency). at least one symptom must have a severity of "5cm" on the neurological symptom vas at screening. see the list of symptoms below: extreme fatigue: feeling overtired with low energy and a strong desire to sleep brain fog: a diminished mental capacity marked by the inability to concentrate, think or reason clearly interferes with daily activities. headache: sharp or dull reoccurring or intermittent that were not present pre-illness. sleep issues: any sleep disturbances in sleep quality that makes sleep seem inadequate or unrefreshing like insomnia or hypersomnia. loss of taste/smell: a diminished sense of taste or smell. 5. study participants should be able to read, understand, and provide written consent. 6. female study participants should not be pregnant or plan to become pregnant during study participation and six months after the last investigational product administration. 7. if their sexual partners can become pregnant, male participants should use a method of contraception during study participation and for six months after the last administration of the experimental drug. * 8. the study participant is able and willing to comply with the requirements of this clinical trial.